

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/786,324	02/26/2004	Pooran Chand	21663-00212-US2	1953
30678 7590 03/03/2006		EXAMINER		
• • • • • • • • • • • • • • • • • • • •	BOVE LODGE & HU	BERCH, MARK L		
SUITE 800 1990 M STREET NW			ART UNIT	PAPER NUMBER
WASHINGTON, DC 20036-3425			1624	

DATE MAILED: 03/03/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	10/786,324	CHAND ET AL.
Office Action Summary	Examiner	Art Unit
	Mark L. Berch	1624
The MAILING DATE of this communic Period for Reply	ation appears on the cover sheet w	ith the correspondence address
A SHORTENED STATUTORY PERIOD FO THE MAILING DATE OF THIS COMMUNIC - Extensions of time may be available under the provisions of after SIX (6) MONTHS from the mailing date of this commu - If the period for reply specified above is less than thirty (30) - If NO period for reply is specified above, the maximum statt - Failure to reply within the set or extended period for reply w Any reply received by the Office later than three months afte earned patent term adjustment. See 37 CFR 1.704(b).	CATION. f 37 CFR 1.136(a). In no event, however, may a nication. d days, a reply within the statutory minimum of thi utory period will apply and will expire SIX (6) MOI rill, by statute, cause the application to become A	reply be timely filed rty (30) days will be considered timely. NTHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed	on	
2a) This action is FINAL . 2b	b)⊠ This action is non-final.	
3) Since this application is in condition for closed in accordance with the practice	•	•
Disposition of Claims		
4) ⊠ Claim(s) <u>1-6</u> is/are pending in the app 4a) Of the above claim(s) is/are 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☒ Claim(s) <u>1-6</u> are subject to restriction	e withdrawn from consideration.	
Application Papers		
9)☐ The specification is objected to by the	Examiner.	
10)☐ The drawing(s) filed on is/are:	• • •	•
Applicant may not request that any object		· ' '
Replacement drawing sheet(s) including to 11) The oath or declaration is objected to I	•	
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for a) All b) Some * c) None of: 1. Certified copies of the priority do some * Copies of the priority do some * Copies of the priority do some * See the attached detailed Office action	ocuments have been received. ocuments have been received in A f the priority documents have beer al Bureau (PCT Rule 17.2(a)).	Application No received in this National Stage
Attachment(s)		
1) Notice of References Cited (PTO-892)	4) Interview	Summary (PTO-413)
 Notice of Draftsperson's Patent Drawing Review (PTG3) Information Disclosure Statement(s) (PTO-1449 or Paper No(s)/Mail Date 		s)/Mail Date nformal Patent Application (PTO-152)

Application/Control Number: 10/786,324 Page 2

Art Unit: 1624

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims (none) drawn to Adenines, classified in class 544, subclass 277.
- II. Claims (none) drawn to Guanines, classified in class 544, subclass 276.
- III. Claims (none), drawn to thymines and uracils, classified in class 544, subclass 312.
- IV. Claims (none) drawn to Cytosines, classified in class 544, subclass 317.
- V. Claims (none), drawn to Others, classified in class 544 and 546, subclass various.

The last group include choices such as halopurines, Xanthines, hypoxanthines, assorted other unfused pyrimidines, imidazopyridines, pyrrolopyrimidines, benzimidazoles, etc.

Claims 1-6 link all the groups and will be examined to the extent that these read on the elected invention.

The inventions are distinct, each from the other because of the following reasons:

Groups I-V are distinct as seen by their marked structural differences. Guanines, Cytosines, etc are considered separate types of compounds, and these different in the number of rings present and the number and nature of the heteroatoms present. These are well recognized as being markedly different in their biological effects. For example, AZT is an effective anti-AIDS drug, but if the thymine is replaced by adenine, cytosine, etc, there is no effectiveness. Similarly, if the guanine in Acyclovir or carbovir is replaced by uracil, a 6-halopurine, etc, the effectiveness is lost.

In the event that the last group is elected, as single choice for the variable B must be made.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

A telephone call was made to Mr. Amernick on 2/22/2006 to request an oral election to the above restriction requirement, but did not result in an election being made. A written restriction was requested.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Application/Control Number: 10/786,324

Art Unit: 1624

Page 4

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mark L. Berch whose telephone number is 571-272-0663.

The examiner can normally be reached on M-F 7:15 - 3:45.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on (571)272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Mark L. Berch Primary Examiner Art Unit 1624

2/27/06